High uptake of 68Ga-PSMA and 18F-DCFPyL in the peritumoral area of rat gliomas due to activated astrocytes

High uptake of 68Ga-PSMA and 18F-DCFPyL in the peritumoral area of rat gliomas due to activated astrocytes

Abstract Background Recent studies reported on high uptake of the PSMA ligands [68Ga]HBED-CC (68Ga-PSMA) and 18F-DCFPyL in cerebral gliomas. This study explores the regional uptake and cellular targets of 68Ga-PSMA and 18F-DCFPyL in three different rat glioma models. Methods F98, 9 L, or U87 rat gli...

Full description

Bibliographic Details
Main Authors:	Dennis Oliveira, Carina Stegmayr, Alexander Heinzel, Johannes Ermert, Bernd Neumaier, N. Jon Shah, Felix M. Mottaghy, Karl-Josef Langen, Antje Willuweit
Format:	Article
Language:	English
Published:	SpringerOpen 2020-05-01
Series:	EJNMMI Research
Online Access:	http://link.springer.com/article/10.1186/s13550-020-00642-0

Similar Items

Intra-individual comparison of 68Ga-PSMA-11 and 18F-DCFPyL normal-organ biodistribution
by: Gonçalo Ferreira, et al.
Published: (2019-05-01)

Uptake in non-affected bone tissue does not differ between [18F]-DCFPyL and [68Ga]-HBED-CC PSMA PET/CT.
by: Jochen Hammes, et al.
Published: (2018-01-01)

PSMA-Targeted PET Radiotracer [18F]DCFPyL as an Imaging Biomarker in Inflammatory Bowel Disease
by: Ismail MS, et al.
Published: (2023-12-01)

Evaluation of 18F-DCFPyL PSMA PET/CT for Prostate Cancer: A Meta-Analysis
by: Ke-Hao Pan, et al.
Published: (2021-02-01)

Threshold for defining PSMA-positivity prior to 177Lu-PSMA therapy: a comparison of [68Ga]Ga-PSMA-11 and [18F]F-DCFPyL in metastatic prostate cancer
by: Jan Heilinger, et al.
Published: (2023-09-01)

Salivary excretion of systemically injected [18F]DCFPyL in prostate cancer patients undergoing PSMA scans
by: Bruna Fernandes, et al.
Published: (2024-04-01)

18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer
by: Aruz Mesci, et al.
Published: (2023-03-01)

Competitive blocking of salivary gland [18F]DCFPyL uptake via localized, retrograde ductal injection of non-radioactive DCFPyL: a preclinical study
by: Jyoti Roy, et al.
Published: (2021-07-01)

Intra-patient comparison of physiologic 68Ga-PSMA-11 and 18F-DCFPyL PET/CT uptake in ganglia in prostate cancer patients: a pictorial essay
by: Medhat M. Osman, et al.
Published: (2021-04-01)

A new automated and putatively versatile synthesis of the PSMA-ligand derivative [18F]DCFPyL using the FASTlabTM synthesizer
by: Raphaël Hoareau, et al.
Published: (2022-05-01)

PSMA-targeted [18F]DCFPyL PET/CT-avid lesions in a patient with prostate cancer: Clinical decision-making informed by the PSMA-RADS interpretive framework
by: Diane K. Reyes, et al.
Published: (2019-03-01)

18F DCFPyL PSMA avid biopsy proven subcutaneous capillary haemangioma as a malignancy mimic in the setting of biochemical recurrent prostate carcinoma
by: Manvinder Dhillon, MBBS, BMedSci, PGDAAD, MS, et al.
Published: (2022-06-01)

Standardized uptake values are adequate measures of [18F]DCFPyL PSMA PET/CT uptake in patients with low prostate cancer disease burden
by: Y.J.L. Bodar, et al.
Published: (2020-11-01)

18F-DCFPyL PET/CT in Newly Diagnosed Prostate Cancer: Diagnostic Value of Intraprostatic PSMA Uptake in Risk Classification of Prostate Cancer
by: Shuoming Zhou, et al.
Published: (2022-02-01)

Diagnosing small bowel carcinoid tumor in a patient with oligometastatic prostate cancer imaged with PSMA-Targeted [18F]DCFPyL PET/CT: Value of the PSMA-RADS-3D Designation
by: Eugene Shenderov, et al.
Published: (2018-03-01)

<sup>18</sup>F-DCFPyL (PSMA) PET in the Management of Men with Biochemical Failure after Primary Therapy: Initial Clinical Experience of an Academic Cancer Center
by: Ur Metser, et al.
Published: (2021-08-01)

Short-duration dynamic [18F]DCFPyL PET and CT perfusion imaging to localize dominant intraprostatic lesions in prostate cancer: validation against digital histopathology and comparison to [18F]DCFPyL PET/MR at 120 minutes
by: Dae-Myoung Yang, et al.
Published: (2021-10-01)

Assessment of 18F-DCFPyL PSMA PET/CT and PET/MR quantitative parameters for reference standard organs: Inter-reader, inter-modality, and inter-patient variability.
by: Edward M Lawrence, et al.
Published: (2023-01-01)

Assessment of 18F-DCFPyL PSMA PET/CT and PET/MR quantitative parameters for reference standard organs: Inter-reader, inter-modality, and inter-patient variability
by: Edward M. Lawrence, et al.
Published: (2023-01-01)

Clinical verification of 18F-DCFPyL PET-detected lesions in patients with biochemically recurrent prostate cancer.
by: Dennie Meijer, et al.
Published: (2020-01-01)

The diagnostic performance of 18F-DCFPyL PET in patients with suspected prostate cancer: A systemic review and meta-analysis
by: Wenyang Pang, et al.
Published: (2023-03-01)

18F-DCFPyL PET/CT in advanced high-grade epithelial ovarian cancer: A prospective pilot study
by: Ur Metser, et al.
Published: (2022-10-01)

Utilization of Salvage and Systemic Therapies for Recurrent Prostate Cancer as a Result of 18F-DCFPyL PET/CT Restaging
by: Wei Liu, MD, et al.
Published: (2021-01-01)

Association of True Positivity with Serum Prostate-Specific Antigen Levels and Other Clinical Factors in Indeterminate PSMA-RADS-3A Lesions Identified on <sup>18</sup>F-DCFPyL PET/CT Scans
by: Tushar Garg, et al.
Published: (2022-10-01)

Optimization and validation of 18F-DCFPyL PET radiomics-based machine learning models in intermediate- to high-risk primary prostate cancer.
by: Wietske I Luining, et al.
Published: (2023-01-01)

Hybrid PET/MRI in Cerebral Glioma: Current Status and Perspectives
by: Karl-Josef Langen, et al.
Published: (2023-07-01)

Performance of 18F-DCFPyL PET/CT Imaging in Early Detection of Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-Analysis
by: Jiale Sun, et al.
Published: (2021-04-01)

Higher Preoperative Maximum Standardised Uptake Values (SUV<sub>max</sub>) Are Associated with Higher Biochemical Recurrence Rates after Robot-Assisted Radical Prostatectomy for [<sup>68</sup>Ga]Ga-PSMA-11 and [<sup>18</sup>F]DCFPyL Positron Emission Tomography/Computed Tomography
by: Katelijne C. C. de Bie, et al.
Published: (2023-07-01)

PSA-Stratified Performance of [<sup>18</sup>F]DCFPyL PET/CT in Biochemically Recurrent Prostate Cancer Patients under Androgen Deprivation Therapy
by: Sara Harsini, et al.
Published: (2022-09-01)

Complex implementation factors demonstrated when evaluating cost-effectiveness and monitoring racial disparities associated with [18F]DCFPyL PET/CT in prostate cancer men
by: Kritika Subramanian, et al.
Published: (2023-05-01)

Comparative study of 18F-DCFPyL PET/CT and 99mTc-MDP SPECT/CT bone imaging for the detection of bone metastases in prostate cancer
by: Xiongjian Hu, et al.
Published: (2023-07-01)

Complete biochemical response after stereotactic ablative radiotherapy of an isolated prostate cancer pelvic soft tissue recurrence detected by 18F-DCFPyL PET/CT
by: Ryan M. Phillips, et al.
Published: (2018-01-01)

Peritumoral/vascular expression of PSMA as a diagnostic marker in hepatic lesions
by: Wei Chen, et al.
Published: (2020-07-01)

Analytical performance validation of aPROMISE platform for prostate tumor burden, index and dominant tumor assessment with 18F-DCFPyL PET/CT. A pilot study
by: Ana María García Vicente, et al.
Published: (2024-02-01)

High SUVs Have More Robust Repeatability in Patients with Metastatic Prostate Cancer: Results from a Prospective Test-Retest Cohort Imaged with 18F-DCFPyL
by: Rudolf A. Werner, et al.
Published: (2022-01-01)

[68Ga]Ga-PSMA PET/MRI, histological PSMA expression and preliminary experience with [177Lu]Lu-PSMA therapy in relapsing high-grade glioma
by: Peter Truckenmueller, et al.
Published: (2022-09-01)

External Validation of Two Nomograms Developed for 68Ga-PSMA-11 Applied to the Prostate-specific Membrane Antigen Tracer 18F-DCFPyl: Is Prediction of the Optimal Timing of Salvage Therapy Feasible?
by: Henk B. Luiting, et al.
Published: (2021-06-01)

Glioma‐induced peritumoral hyperexcitability in a pediatric glioma model
by: Lata Chaunsali, et al.
Published: (2020-10-01)

Using 18F-DCFPyL Prostate-Specific Membrane Antigen–Directed Positron Emission Tomography/Magnetic Resonance Imaging to Define Intraprostatic Boosts for Prostate Stereotactic Body Radiation Therapy
by: John M. Floberg, MD, PhD, et al.
Published: (2023-09-01)

Peritumoral Edema in Gliomas: A Review of Mechanisms and Management
by: Kazufumi Ohmura, et al.
Published: (2023-10-01)